8 not yet recruiting, 5 recruiting, 3 completed, 1 active not recruiting. 8 Not applicable, 5 Phase 2, 3 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow Prostate Cancer Patients: new trials by email Literature Review of Prostate Cancer Patients trials Research Report on Prostate Cancer Patients
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AI Chatbot for Prostate Radiation Therapy Patient Education AI Educational Chatbot - Prostate Cancer Patients | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 50 | 2026-12-01 | 2026-09-17 |
| Dyadic STEP-SexPCare for Sexual Health in Chinese Prostate Cancer Survivors and Their Female Partners Dyadic STEP-SexPCare, Standard Survivorship Care - Prostate Cancer Patients, Sexual Dysfunctions | Not applicable | Not yet recruiting | The University of Hong Kong | 72 | 2026-10-01 | 2026-09-21 |
| Expanding Genetic Access for Prostate Cancer Survivors Print Genetic Education Guide, Digital Guide Genetic Education Guide, Enhanced Usual Care - Prostate Cancer Patients, Hereditary Cancer | Not applicable | Not yet recruiting | Georgetown University | 500 | 2026-08-01 | 2026-06-01 |
| Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer. Darolutamide, docetaxel, ADT - Prostate Cancer, Prostate | Phase 2 | Not yet recruiting | RenJi Hospital | 200 | 2026-08-01 | 2026-07-28 |
| Radiation Therapy Approaches for People With Prostate Cancer Standard of Care HDR Brachytherapy, SBRT - Prostate Cancer Patients, Non-metastatic Prostate Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 126 | 2026-07-31 | 2026-08-12 |
| 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial Darolutamide combined with 177Lu-PSMA-617 - Prostate Cancer, Prostate Cancer Patients | Phase 4 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2026-07-01 | 2026-07-01 |
| Effects of Combined Training in Prostate Cancer Patients Combined training - Prostate Cancer Patients, Androgen Deprivation Therapy | Not applicable | Not yet recruiting | Universidade Federal de Santa Catarina | 46 | 2026-06-15 | 2026-07-02 |
| A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer Enzalutamide Dose Escalation, Standard of Care - Prostate Cancer Patients, Elderly Patients | Phase 2 | Not yet recruiting | Sunnybrook Health Sciences Centre | 26 | 2026-04-01 | 2026-04-06 |
| Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody - Prostate Cancer Patients, Non-castrate Prostate Cancer | Phase 1 | Recruiting | University of Wisconsin, Madison | 14 | 2026-03-03 | 2026-03-11 |
| A Digitally Distributed Yoga Intervention in Prostate Cancer Rehabilitation : Protocol for a Randomized Controlled Trial Digital yoga intervention - Prostate Cancer Patients | Not applicable | Not yet recruiting | Region Örebro County | 220 | 2026-01-10 | 2025-09-05 |
| Evaluation of Needs of Patients and Care-givers During and After Radiotherapy of Patients With Prostate Cancer Interview - Prostate Cancer Patients | Not applicable | Recruiting | Charite University, Berlin, Germany | 60 | 2025-08-01 | 2025-09-05 |
| Cancer Survivors Program active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening - Prostate Cancer Patients, Breast Cancer Patients | Not applicable | Recruiting | Masaryk Memorial Cancer Institute | 200 | 2025-05-05 | 2026-06-11 |
| Hypo Fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer Hypofractionated Intensity-Modulated Radiation Therapy, Conventional Intensity-Modulated Radiation Therapy - Hypofractionated Dose, Prostate Cancer Patients | Not applicable | Completed | Tanta University | 60 | 2022-06-30 | 2026-03-24 |
| The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680 - Prostate Cancer Patients | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2020-06-15 | 2023-02-09 |
| Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion Repaglinide, Bupropion and SHR3680 - Prostate Cancer Patients | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 18 | 2020-06-01 | 2020-12-11 |
| Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) SBRT + Durvalumab, SBRT - Node; Prostate, Bone Metastases | Phase 2 | Active not recruiting | Institut Cancerologie de l'Ouest | 96 | 2019-03-21 | 2026-03-31 |
| C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer 11C-Acetate - Prostate Cancer Patients | Early Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 6 | 2016-03-01 | 2022-05-18 |
| A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin - Prostate Cancer Patients | Phase 2 / Phase 3 | Recruiting | Shanghai Jiao Tong University School of Medicine | 300 | 2015-01-01 | 2026-01-12 |
Prostatic Neoplasms (11) · Breast Neoplasms (1) · Motor Activity (1)
Genital Diseases (11) · Genital Diseases, Male (11) · Genital Neoplasms, Male (11) · Male Urogenital Diseases (11) · Neoplasms (11) · Neoplasms by Site (11) · Prostatic Diseases (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Behavior (1) · Breast Diseases (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Docetaxel (2) · Bupropion (1) · Dermatoglyphics (1) · Interviews as Topic (1) · Midazolam (1) · Mitoxantrone (1) · Nivolumab (1) · Omeprazole (1) · Pluvicto (1) · Radiosurgery (1) · Standard of Care (1) · Warfarin (1) · cabazitaxel (1) · carbon-11 acetate (1) · darolutamide (1)
Jiangsu HengRui Medicine Co., Ltd. (2) · Abramson Cancer Center at Penn Medicine (1) · Brigham and Women's Hospital (1) · Charite University, Berlin, Germany (1) · Georgetown University (1) · Institut Cancerologie de l'Ouest (1) · Masaryk Memorial Cancer Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Region Örebro County (1) · RenJi Hospital (1) · Shanghai Jiao Tong University School of Medicine (1) · Sunnybrook Health Sciences Centre (1) · Tanta University (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The University of Hong Kong (1)
China (4) · United States (4) · Canada (1) · Czechia (1) · Egypt (1) · France (1) · Germany (1) · Sweden (1)
Dan Pryma, MD (1) · Daniel Gorovets, MD (1) · Daniel Khalaf, MD (1) · Douglas McNeel, MD, PhD (1) · Emma Ohlsson-Nevo (1) · Nada El-Behiri (1) · Weiqing Han, Ph.D (1) · Yu Sun, Ph.D (1)
R01CA296911 (1)